Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving viable micro-organism
Reexamination Certificate
2004-01-27
2008-03-18
Mosher, Mary E. (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving viable micro-organism
C435S005000
Reexamination Certificate
active
07344853
ABSTRACT:
Encephalotoxin produced by activated mononuclear phagocytes is present in individuals having neurological disease including neurodegenerative and neuro-inflammatory diseases, such as Alzheimer's disease (AD), HIV-1-associated dementia (HAD), Creutzfeldt-Jakob Disease, Mild Cognitive Impairment, prion disease, minor cognitive/motor dysfunction, acute stroke, acute trauma, or neuro-AIDS. Biochemical detection of encephalotoxin according to the methods of the invention will allow diagnosis of neurological disease in early, presymptomatic stages, thereby allowing early intervention in disease progression as well as identification of subjects or populations at risk for developing neurodegenerative disease. The methods of the invention also provide a mechanism for monitoring progression and treatment of neurological disease.
REFERENCES:
patent: 2546658 (1951-03-01), Surrey
patent: 3689671 (1972-09-01), Johnston et al.
patent: 3702362 (1972-11-01), Shen et al.
patent: 3715375 (1973-02-01), Shen et al.
patent: 3775403 (1973-11-01), Shen et al.
patent: 3775444 (1973-11-01), Jensen et al.
patent: 3786050 (1974-01-01), Shen et al.
patent: 4338334 (1982-07-01), Jensen et al.
patent: 5532219 (1996-07-01), McGeer
patent: 6043283 (2000-03-01), Giulian
patent: 6071493 (2000-06-01), Giulian
patent: 6451544 (2002-09-01), Giulian
patent: 6475742 (2002-11-01), Giulian
patent: 6475745 (2002-11-01), Giulian
patent: 2001/0016326 (2001-08-01), Giulian
patent: 2001/0016327 (2001-08-01), Giulian
patent: 2002/0198231 (2002-12-01), Nelson
patent: WO 2004/066940 (2004-08-01), None
patent: WO 2004/066943 (2004-08-01), None
Collinge J. (2001). “Prion diseases of humans and animals: Their causes and molecular basis”. Annu Rev Neurosci 24: 519-50.
55 FR 9576, Mar. 14, 1990; Part 493.1253 (see http://www.phppo.cdc.gov/clia/regs/toc.aspx).
Aisen, P.S., et al., “Inflammatory mechanisms in Alzheimer's disease: implications for therapy,”Am. J. Psychiatry, 1994, 151, 1105-1113.
Al-Haideri, M., et al., “Heparan sulfate proteoglycan-mediated uptake of apolipoprotein E-triglyceride-rich lipoprotein particles: a major pathway at physiological particle concentrations,”Biochemistry, 1997, 36, 12766-12772.
Andreasen, N., et al., “Cerebrospinal fluid beta-amyloid sub (1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease,”Archives Neurology, 1999, 56(6), 673-680 (attached pp. 1-13).
Andreasen, N., et al., “Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample,”Neurology, 1999, 53, 1488-1494.
Appel, V., et al., “A rating scale for amyotrophic lateral sclerosis: description and preliminary experience,”Ann. Neurol., 1987, 22, 328-333.
Asare, E., et al., “Neuronal pattern correlates with severity of human immunodeficiency virus-associated dementia complex,”Am. J. Path, 1996, 148(1), 31-38.
Bales, K.R., et al., “Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition,”Nat. Genet., 1997, 17, 263-264.
Bales, K.R., et al., “Neuroinflammation and Alzheimer's disease: critical roles for cytokine/Aβ-induced glial activation, NF-κB, and apolipoprotein E,”Neurobiol. Aging, 2000, 21, 427-432.
Bame, K.J., et al., “Aβ(1-40) prevents heparanase-catalyzed degration of heparin sulfate glycosaminoglycans and proteoglycans in vitro. A role for heparin sulfate proteoglycan turnover in Alzheimer's disease,”J. Biol. Chem., 1997, 272(27), 17005-17011.
Banati, R.B., et al., “Cytotoxicity of microglia,”Glia, 1993, 7, 111-118.
Berg, L., et al., “Clinical demential rating (CDR),”Psychopharmacol Bull., 1988, 24(4), 637-639.
Bigio, E.H., et al., “Synapse loss may be a minor contributor to decreased regional cerebral blood flow in Alzheimer disease,”Dement. Geriatr. Cong. Disord., 2003, 15, 72-78.
Bigio, E.H., et al., “Synapse loss is greater in presenile than senile onset Alzheimer disease,”Neuropath. App. Neurobiol., 2002, 28, 218-227.
Bischkopf, J., et al., “Mild cognitive impairment1—a review of prevalence, incidence and outcome according to current approaches,”Acta Psychiatr. Scand., 2002, 106, 403-414.
Blessed, G., et al., “The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects,”Br. J. Psychiat., 1968, 114, 797-811.
Boireau, A., et al., “Thalidomide reduces MPTP-induced decrease in striatal dopamine levels in mice,”Neurosci. Lett., 1997, 234, 123-126.
Boje, K.M., et al., “Microglial-produced nitric oxide and reactive nitrogen oxides mediate neuronal cell death,”Brain Res., 1992, 587, 250-256.
Bonney, R.J., et al., “Physiological and pharmacological regulation of prostaglandin and leukotriene production by macrophages,”J. of Leukocyte Biol., 1984, 35, 1-10.
Bornemann, K.D., et al., “Transgenic mouse models of Alzheimer's disease,”Annu. NY Acad. Sci., 2000, 908, 260-266.
Borst, P., et al., “New mechanisms of drug resistance in parasitic protozoa,”Annul. Rev. Microbiol, 1995, 49, 427-460.
Breitner, J.C.S., et al., “Inverse association of anti-inflammatory treatments and Alzheimer's disease: Initial results of a co-twin control study,”Neurology, 1994, 44, 227-232.
Bronfman, F.C., et al., “No evidence for cholinergic problems in apolipoprotein E knockout and apolipoprotein E4 transgenic mice,”Neurosci., 2000, 97(3), 411-417.
Buttini, M., et al., “Expression of human apolipoprotein E3 or E4 in the brains of apoE-/-mice: isoform-specific effects on neurodegeneration,”J. Neurosci., 1999, 19(2), 4867-4880.
Campbell, J.H., et al., “Heparan sulfate-degrading enzymes induce modulation of smooth muscle phenotype,”Exp. Cell Res., 1992, 200, 156-167.
Carlsson, J., et al., “Clinical relevance of the quantification of apolipoprotein E in cerebrospinal fluid,”Clin. Chim. Acta, 1991, 196, 167-176.
Castillo, G.M., et al., “The sulfate moieties of glycosaminoglycans are critical for the enhancement of β-amyloid protein fibril formation,”J. of Neurochen., 1999, 72, 1681-1687.
Chao, C., et al., “Activated microglia mediate neuronal cell injury via a nitric oxide mechanism,”J. Immunology, 1992, 149, 2736-2741.
Chaudhary, P.M., et al., “Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells,”Cell, 1991, 66, 85-94.
Clemens, J.A., et al., “Implants containing β-amyloid protein are not neurotoxic to young and old rat brain,”Neurobiol. Aging, 1992, 13, 581-586.
Colton, C.A., et al., “Production of superoxide anion by a CNS macrophage, the microglia,”FEBS Lett., 1987, 223(2), 284-288.
“Consensus recommendations for the postmortem diagnosis of Alzheimer's disease,”Neurobiol. Aging, 1997, 18(S4), S1-S2.
Corder, E.H., et al., “Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease,”Nat. Genet., 1994, 7, 180-183.
Corder, E.H., et al., “Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families,”Science, 1993, 261, 921-923.
Corder, E., et al., “HIV-1-infected subjects with the E4 allele for APOE have excess dementia and peripheral neuropathy,”Nature Medicine, 1998, 4(10), 1182-1184.
Cotman, C.W., et al., “β-amyloid neurotoxicity: a discussion of in vitro findings,”Neurobiol. Aging, 1992, 13, 587-590.
Cotman, S.L., et al., “Agrin binds to β-amyloid (Aβ), accelerates Aβ fibril formation, and is localized to Aβ deposits in Alzheimer's disease brain,”Mol. Cell. Neurosci., 2000, 15, 183-198.
D'Agostino, R.B., et al., “A suggestion for using powerful and informative tests of norm
Baylor College of Medicine
Mosher Mary E.
Snyder Stuart W.
Woodcock & Washburn LLP
LandOfFree
Methods for diagnosis and monitoring of neurological disease... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for diagnosis and monitoring of neurological disease..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for diagnosis and monitoring of neurological disease... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3979434